Home pageNTLA • NASDAQ
add
Intellia Therapeutics Inc
10,55 $
After Hours:(0,00%)0,00
10,55 $
Data e ora chiusura: 27 gen, 16:09:34 GMT-5 · USD · NASDAQ · Disclaimer
Chiusura precedente
10,99 $
Intervallo giornaliero
10,11 $ - 10,77 $
Intervallo annuale
9,25 $ - 34,87 $
Cap di mercato
1,07 Mld USD
Volume medio
2,85 Mln
Rapporto P/E
-
Dividendo/Prezzo
-
Borsa valori principale
NASDAQ
Notizie
Dati finanziari
Conto economico
Entrate
Utile netto
| (USD) | set 2024info | Variazione Y/Y |
|---|---|---|
Entrate | 9,11 Mln | -24,02% |
Spese di gestione | 30,50 Mln | 3,73% |
Utile netto | -135,71 Mln | -11,04% |
Margine di profitto netto | -1489,54 | -46,15% |
Utili per azione | -1,34 | 2,90% |
EBITDA | -142,16 Mln | -10,36% |
Aliquota fiscale effettiva | — | — |
Stato patrimoniale
Totale attivo
Totale passivo
| (USD) | set 2024info | Variazione Y/Y |
|---|---|---|
Investimenti cash/breve termine | 658,11 Mln | -23,01% |
Totale attivo | 1,17 Mld | -5,63% |
Totale passivo | 210,74 Mln | 2,33% |
Patrimonio netto totale | 962,62 Mln | — |
Azioni in circolazione | 101,85 Mln | — |
Prezzo/valore contabile | 1,16 | — |
Redditività dell'attivo | -30,61% | — |
Rendimento sul capitale | -33,80% | — |
Flusso di cassa
Flusso di cassa netto
| (USD) | set 2024info | Variazione Y/Y |
|---|---|---|
Utile netto | -135,71 Mln | -11,04% |
Liquidità di esercizio | -84,84 Mln | 16,32% |
Contanti da investimenti | -7,71 Mln | -109,70% |
Contanti da finanziamenti | 82,19 Mln | 330,28% |
Flusso di cassa netto | -10,35 Mln | -272,58% |
Flusso di cassa libero | -35,80 Mln | 44,08% |
Informazioni
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
CEO
Fondazione
2014
Sito web
Dipendenti
526
